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ABSTRACT 
 
 
Cancer is a primary cause of morbidity and mortality worldwide. In Malaysia, cancer was 
among the top five causes of death in the Ministry of Health (MOH) hospitals. Over the 
past 20 years, leukaemia treatments have advanced rapidly. Acute Myeloid Leukaemia 
(AML) is one of the most common and acute diseases among different types of 
leukaemia. Due to increased number of AML cases and high cost of treatments, drug 
utilization evaluation of AML is important for allocation of healthcare resource. This is a 
retrospective drug utilization study of chemotherapy regimen for AML patients in 
Ampang Hospital. Patient’s data were extracted from electronic Health Information 
System known as e-HIS system. The objective of the study is to describe the utilization of 
chemotherapy regimen drugs for AML patients. The specific objectives for this study are 
to describe characteristic of AML patients, to identify types of chemotherapy regimen 
drugs used in AML patients, to identify side effect of chemotherapy used and to examine 
the complete remission (CR) rate and overall survival for AML patients. A total of 133 
records were retrieved with the median age of 41 years old ranged from 13 to 74 years 
old. The most commonly prescribed induction regimen was DA regimen. The most 
commonly used consolidation chemotherapy was HIDAC regimen and for salvage 
chemotherapy was FLAG-Ida regimen. Total of 108 patients had achieved CR with 
duration between 0.5 to 79 months and median of 17 months. Of the 108 patients 
achieved CR, 39 patients relapsed at a median of 9 months, 22 patients died in CR at a 
median of 5.5 months and 47 patients remain alive in CR1 with a median of 34 months. 
Regardless of the age, gender and ethnicity, the regression result showed that only 
transplant had a significant effect to the CR (P<0.05) and increased odds of CR by 2.8 
times than AML patients who are not undergo transplant. Total of 83 AML patients had 
died during the study period (62.4%). Regardless of the age, gender and ethnicity, only 
CR had a significant effect to the mortality (P<0.05). AML patients who achieved CR 
have decreased odds of mortality by 66% than AML patients who are not achieved CR. 
Overall survival (OS) rate at 2 years was 28.6% and OS rate at 5 years was 9%. The 
median OS was 20 months (95% CI: 15.4 to 24.6 months). There was clinically 
significant difference of median OS between transplant patients and non-transplant 
patients with the p-value <0.05. From this study, the regression result showed that AML 
patients who achieved CR have increased odds of survival by 2.93 times than AML 
patients who are not achieved CR. From this study, all chemotherapy regimens in either 
induction phase, consolidation phase or salvage phase have been used in accordance with 
their appropriate indications and follow the international guideline. These results should 
increase understanding of chemotherapy utilization pattern in making evidence based 
decision among physician and pharmacist. 
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